Wide Open Agriculture appoints Craig Swan as CEO and pivots to a contract manufacturing model to improve economics and scale lupin protein production, while receiving a A$1.69 million R&D tax rebate.
- Craig Swan appointed CEO to drive commercial scale-up
- Exploring capital light contract manufacturing to reduce costs
- Reduced lupin protein output at German facility amid transition
- Toll manufacturing revenue grows with third-party pea protein processing
- Received A$1.69 million R&D tax rebate strengthening cash position
New Leadership Signals Strategic Pivot
Wide Open Agriculture Ltd (ASX:WOA) has handed the reins to Craig Swan as CEO, effective 7 April 2026, marking a clear shift in strategy towards commercial scaling and capital efficiency. Swan arrives with a pedigree in B2B food ingredients, having held senior roles at Givaudan, Goodman Fielder Ingredients, and Nutrasweet, with significant experience across Asia, including China and Singapore; key markets for WOA. His appointment underscores the company’s ambition to refine the economics of its lupin protein platform and accelerate growth.
Former CEO Matthew Skinner steps back to the board as a non-executive director, retaining his operational expertise, while Claudia Kwan has resigned from the board but remains a strategic advisor. This leadership reshuffle follows WOA’s earlier announcement of Swan’s appointment and sets the tone for a more commercially focused phase.
Pivot to Capital Light Manufacturing and Facility Rationalisation
WOA is actively investigating a capital light contract manufacturing model for its lupin protein production, aiming to slash unit costs and speed up scale-up. This approach would leverage third-party producers in lower-cost jurisdictions, potentially delivering lower energy and labour expenses, stronger gross margins, and reduced fixed overheads compared to the company’s German facility.
The German plant, primarily designed for protein extraction rather than whole-of-seed processing, saw a reduction in lupin protein output during the quarter. High EU energy and labour costs have compressed economics at current production levels, prompting WOA to consider alternatives. While the facility was crucial in establishing initial commercial-scale production and securing regulatory approvals, including in China, it is not optimally configured for industrial-scale whole-of-seed processing without further capital investment.
Meanwhile, the German site’s underutilised capacity is being partially offset by increased toll manufacturing, processing pea protein for a third-party customer. This non-competing activity has boosted revenue modestly and absorbed some fixed costs, with early discussions underway for a potential longer-term agreement. No forecast has been provided on the likelihood of securing this deal.
Technical Trials and Whole-of-Seed Monetisation Progress
WOA continues to refine its production processes through laboratory and pilot scale trials, exploring alternative de-oiling methods, ultrafiltration to improve protein yield and quality, and fibre product development. These efforts aim to reduce manufacturing costs and enhance product performance.
The company has also recorded non-material sales of lupin oil, advancing its whole-of-seed monetisation strategy that targets revenue streams from protein, oil, and fibre. This diversified approach could underpin the next phase of growth by extracting maximum value from each tonne of lupin processed.
Financial Position Bolstered by R&D Tax Incentive
WOA’s balance sheet received a welcome boost with the receipt of a A$1,686,579 R&D tax rebate from the Australian Taxation Office post-quarter, reflecting its FY25 innovation efforts across Australian and German operations. This rebate strengthens the company’s cash position, which stood at A$730,000 at quarter-end and approximately A$2 million as of the announcement date.
Operating cash flow remains negative, with net cash used in operating activities at A$768,000 for the quarter. The company is confident in its ability to raise additional funds if needed, although no immediate plans for capital raising have been disclosed.
Commercial Growth Hinges on Contract Manufacturing Decision
WOA’s immediate priority is to conclude its investigation into the contract manufacturing model. A positive outcome could materially improve unit economics and position the company to meet growing customer demand with scalable supply. The company continues active pipeline conversion efforts to secure long-term supply agreements and expand its footprint, supported by regulatory approvals and distribution partnerships, including an exclusive deal with Univar Solutions in China.
This strategic pivot is a natural evolution from earlier phases focused on product validation and regulatory groundwork, as detailed in the company’s recent update on its R&D rebate and commercialisation efforts. The shift towards capital efficiency and broader monetisation reflects a pragmatic response to operational realities and market opportunities.
Bottom Line?
WOA’s future hinges on the success of its contract manufacturing model to unlock scalable, cost-effective lupin production.
Questions in the middle?
- Will WOA secure a long-term manufacturing agreement to stabilise German facility costs?
- How soon can the contract manufacturing model be validated and implemented?
- What impact will the shift to capital light production have on WOA’s competitive position in Asia and Europe?